Drug Trial Radar · NCT07566156
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
390
Planned (sponsor's estimate)
Start
May 11, 2026
Primary completion
Mar 31, 2030
Study completion Feb 29, 2032
Sponsor
- Lead sponsor
- Astellas Pharma Global Development, Inc.Astellas (ALPMY)
- Sponsor type
- Industry
- Collaborators
- Pfizer
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being done to see how well two drugs (enfortumab vedotin and pembrolizumab) work together as a bladder preservation approach to treat patients with muscle invasive bladder cancer. The study will compare these drugs to concurrent chemoradiotherapy that is usually used to treat this cancer (standard of care). The study will enroll patients with muscle-invasive bladder cancer (MIBC) who have cancer that has not spread outside the bladder.
Conditions
- Urothelial Cancer
- Urinary Bladder Neoplasms
Interventions
Enfortumab vedotinDrug
Enfortumab vedotin administered as an IV infusion on Days 1 and 8 of every 3-week cycle up to cycle 9.
Conventional RadiotherapyRadiation
64 Gy in 32 fractions over 6.5 weeks administered to the participant's bladder only or the bladder and prophylactically to pelvic nodes.
Hypofractionated RadiotherapyRadiation
55 Gy in 20 fractions over 4 weeks administered to the participant's bladder only.
CisplatinDrug
40 mg of cisplatin per meter squared of body surface area, administered once weekly via IV infusion during radiation OR 20 mg of cisplatin per meter squared of body surface area per day on Days 1 and 2 weekly via IV infusion during radiation.
FluorouracilDrug
500 mg per meter squared of body surface area per day on Days 1-5 (week 1) and Days 22 26 (week 3) administered as continuous IV infusion during radiation in combination with mitomycin C.
Mitomycin CDrug
12 mg per meter squared of body surface area administered as an IV bolus on Day 1 during radiation in combination with fluorouracil.
GemcitabineDrug
100 mg per meter squared of body surface area administered once weekly via IV infusion during radiation OR 27 mg per meter squared of body surface area administered twice weekly via IV infusion during radiation
PembrolizumabDrug
IV infusion on Day 1 of every 3-week cycle up to cycle 17.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Bladder-intact Event Free Survival (BI-EFS) by Blinded Independent Central Review (BICR)Time frame: Up to approximately 45.5 months
- Overall Survival (OS)Time frame: Up to approximately 60 months
Locations
37 sites in 6 countries. Site status is shown where the registry gives one.
Arkansas Urology
Little Rock, Arkansas · Recruiting
Samsun Clinic - Ridley-Tree Cancer Center
Santa Barbara, California · Recruiting
Rocky Mountain Cancer Center
Aurora, Colorado · Recruiting
Medical Oncology Hematology Consultants
Newark, Delaware · Recruiting
Hope and Healing Clinical Research LLC
Hinsdale, Illinois · Recruiting
Hope and Healing Clinical Research LLC
New Lenox, Illinois · Recruiting
Illinois Cancer Specialists
Niles, Illinois · Recruiting
Fort Wayne Medical Oncology and Hematology
Fort Wayne, Indiana · Recruiting
Comprehensive Urology
Royal Oak, Michigan · Recruiting
Missouri Cancer Associates
Columbia, Missouri · Recruiting
Siteman Cancer Center
St Louis, Missouri · Recruiting
Comprehensive Cancer Centers of Nevada - Southwest
Las Vegas, Nevada · Recruiting
Icahn School of Medicine at Mount Sinai
New York, New York · Recruiting
Oncology Hematology Care Clinical Trials, LLC
Fairfield, Ohio · Recruiting
Williamette Valley Cancer Institute and Research Center
Eugene, Oregon · Recruiting
Compass Oncology - West
Tigard, Oregon · Recruiting
SCRI Oncology Partners
Nashville, Tennessee · Recruiting
Texas Oncology
Austin, Texas · Recruiting
Texas Oncology - Northeast Texas
Tyler, Texas · Recruiting
University of Virginia Comprehensive Cancer Center
Charlottesville, Virginia · Recruiting
Virginia Oncology Associates
Norfolk, Virginia · Recruiting
Site BR01087
Salvador, Estado de Bahia, Brazil · Recruiting
Site BR01093
Barretos, São Paulo, Brazil · Recruiting
Site BR01099
São José do Rio Preto, São Paulo, Brazil · Recruiting
Site CA01194
Chicoutimi, Quebec, Canada · Recruiting
Site CA01052
Montreal, Quebec, Canada · Recruiting
Site CA01071
Montreal, Quebec, Canada · Recruiting
Site FR01078
Nîmes, France · Recruiting
Site KR01113
Daegu, South Korea · Recruiting
Site KR01063
Seongnam-si, South Korea · Recruiting
Site KR01061
Seoul, South Korea · Recruiting
Site KR01064
Seoul, South Korea · Recruiting
Site KR01065
Seoul, South Korea · Recruiting
Site KR01084
Seoul, South Korea · Recruiting
Site KR01085
Seoul, South Korea · Recruiting
Site KR01062
Goyang-si, Gyeonggi-do, South Korea · Recruiting
Site TW01117
Kaohsiung City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.